OrbiMed Raises $3B for Global Healthcare Investing

OrbiMed has raised $3 billion across two new private-market funds focused on life sciences and healthcare investing.

What happened

OrbiMed Private Investments X raised more than $1.9 billion for venture investments in the US and Europe, while OrbiMed Asia Partners VI raised more than $1 billion for healthcare growth equity and venture investments across Asia. The vehicles will invest across biopharma, medical devices, diagnostics and technology-enabled healthcare services. These are investment funds rather than operating-company financings, but the size of the raise gives OrbiMed substantial new capacity to back healthcare companies across stages and regions.

Why it matters

Healthcare venture fundraising has been uneven even as individual biotech rounds have become very large. A $3 billion specialist raise indicates that institutional investors still see significant opportunity in drug development, medical technology and healthcare services, particularly as AI and new therapeutic modalities expand the investable landscape.

The bigger picture

Large specialist funds can shape company formation and financing because they are able to support businesses through multiple rounds. The raise also highlights the concentration of healthcare venture capital in a smaller set of established managers with the scale and track record to attract institutional LPs.